alexa The Use Of New Adjuvants And VLPs For The Development Of Vaccines For Emerging And Infectious Diseases
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

15th Annual Summit on Vaccines and Immunization
February 20-21, 2017 Berlin, Germany

Gustavo Cabral de Miranda
University of Oxford, UK
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.C1.054
Abstract
The increased burden of neglected and emerging infectious disease (EID) has caused a serious global public health threat. According to World Health Organization (WHO), infections such as dengue fever, Zika virus (ZIKV) and malaria are associated with billions of deaths worldwide. For disease prevention and control, vaccination remains the most effective tool. The use of adjuvants in vaccine development is a well-established concept and practice. Adjuvants improve and modulate immune responses to the desired antigen. They increase the half-life of vaccine antigens and improve antigen uptake, processing and presentation by APCs (antigen-presenting cells). Micro-crystalline tyrosine (MCT) is a depot adjuvant formulated in licensed vaccines for use in humans with an excellent safety profile. Virus-like particles (VLPs) have a high capacity to induce strong humoral and cellular immune responses and may have the potential to increase vaccine efficacy against malaria and ZIKV, in particular if combined with MCT. We investigated the impact of MCT and/or VLP presented vaccine antigens and compared to protein antigens formulated with alum. We have demonstrated that MCT is able to produce high and sustained IgG responses that are specific and protective against the sporozoite of P. vivax. Our results showed that malaria antigens conjugated to VLPs and formulated in MCT induced higher antibody and T-cell responses and protected against Plasmodium bergei/vivax. Hence, combining MCT with VLP-conjugate vaccines defines a promising strategy for the development of protective malaria vaccines. We are also investigating the use of VLPs for ZIKV vaccine development. We have induced high antibody titres using domain III (DIII) of the envelope (E) protein of ZIKV. This protein is strictly associated with specific virus neutralization, therefore this vaccination strategy should avoid eliciting cross-reactive antibodies against other Flavivirus, which have been shown previously to have a detrimental effect upon infection with other Flavivirus e.g. Dengue.
Biography

Gustavo Cabral de Miranda is a Post-doctoral Research Scientist in Vaccinology at Jenner Institute, University of Oxford, UK. He has a Degree in Biological Science at Bahia State University; MSc in Immunology at Federal University of Bahia and; PhD in Immunology at University of São Paulo, Brazil. He is currently pursuing his research which focuses on The use of new adjuvants, especially microcrystalline tyrosine (MCT) and phosphatidylserine (PS) derivatives, and virus like particles (VLPs) for the development of vaccines against malaria and Flavivirus, especially Zika virus (ZIKV) and Dengue virus.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords